Sildenafil preserves exercise capacity in patients with idiopathic pulmonary fibrosis and right-sided ventricular dysfunction. - Test2 - elhamkhani - TriplyDB

Sildenafil preserves exercise capacity in patients with idiopathic pulmonary fibrosis and right-sided ventricular dysfunction.

Sildenafil preserves exercise capacity in patients with idiopathic pulmonary fibrosis and right-sided ventricular dysfunction.

http://www.wikidata.org/entity/Q30412726

about

Pharmacological management of IPF Year in review 2015: Interstitial lung disease, pulmonary vascular disease, pulmonary function, sleep and ventilation, cystic fibrosis and paediatric lung disease Pharmacological Treatment of Idiopathic Pulmonary Fibrosis: Current Approaches, Unsolved Issues, and Future Perspectives Under-recognised co-morbidities in idiopathic pulmonary fibrosis: A review Managing comorbidities in idiopathic pulmonary fibrosis The psychometric properties of the St George's Respiratory Questionnaire (SGRQ) in patients with idiopathic pulmonary fibrosis: a literature review Update on diagnosis and treatment of idiopathic pulmonary fibrosis Pulmonary hypertension and right heart dysfunction in chronic lung disease.Pulmonary hypertension's variegated landscape: a snapshot.Bosentan in pulmonary hypertension associated with fibrotic idiopathic interstitial pneumonia Use of pulmonary arterial hypertension-approved therapy in the treatment of non-group 1 pulmonary hypertension at US referral centers Determinants of 6-minute walk distance in patients with idiopathic pulmonary fibrosis undergoing lung transplant evaluation.Echocardiographic and hemodynamic predictors of mortality in idiopathic pulmonary fibrosis.Author reply to the editor.The diagnosis and treatment of idiopathic pulmonary fibrosis Tanshinone IIA attenuates bleomycin-induced pulmonary fibrosis via modulating angiotensin-converting enzyme 2/ angiotensin-(1-7) axis in rats New approaches to modulating idiopathic pulmonary fibrosis.Treatment of pulmonary hypertension in idiopathic pulmonary fibrosis: shortfall in efficacy or trial design?Diagnosis and management of interstitial lung disease.Management of Pulmonary Hypertension in Patients with Chronic Lung Disease.Comorbid Conditions in Idiopathic Pulmonary Fibrosis: Recognition and Management.Chronic use of PAH-specific therapy in World Health Organization Group III Pulmonary Hypertension: a systematic review and meta-analysis Idiopathic Pulmonary Fibrosis and the Elderly: Diagnosis and Management Considerations.Pulmonary hypertension associated with lung diseases and hypoxemia.Treatment of idiopathic pulmonary fibrosis: a position paper from a Nordic expert group.Multi-institutional retrospective cohort study of patients with severe pulmonary hypertension associated with respiratory diseases.The St. George's Respiratory Questionnaire as a prognostic factor in IPF.Novel Therapeutic Strategies for Reducing Right Heart Failure Associated Mortality in Fibrotic Lung Diseases.Changes in right heart haemodynamics and echocardiographic function in an advanced phenotype of pulmonary hypertension and right heart dysfunction associated with pulmonary fibrosis.Recent advances in managing idiopathic pulmonary fibrosis.Riociguat versus sildenafil on hypoxic pulmonary vasoconstriction and ventilation/perfusion matching.Beneficial effects of bile acid receptor agonists in pulmonary disease models.Challenges in Pulmonary Hypertension: Controversies in Treating the Tip of the Iceberg.Haemodynamic changes in pulmonary hypertension in patients with interstitial lung disease treated with PDE-5 inhibitors.An Official ATS/ERS/JRS/ALAT Clinical Practice Guideline: Treatment of Idiopathic Pulmonary Fibrosis. An Update of the 2011 Clinical Practice Guideline.The Selective Angiotensin II Type 2 Receptor Agonist, Compound 21, Attenuates the Progression of Lung Fibrosis and Pulmonary Hypertension in an Experimental Model of Bleomycin-Induced Lung Injury.Pulmonary hypertension due to unclassified interstitial lung disease in a Pembroke Welsh corgi.

P2860

Q26748808-6811C974-3984-4E4F-BE5B-B0DCF780A682 Q26766313-1D420E8D-4E65-4344-B311-9563F6E5A3D9 Q26771309-46910FF0-7205-4850-B6E9-6B29E8CD738E Q26781255-317B7AB7-FC26-483D-BDCB-E29CBA07AC91 Q26785617-6D4746BE-4ADF-4B38-9272-DEE5F9208E2E Q26992007-6BDF3BED-A9D4-48C9-B561-97374F7FA6CC Q28083702-DC45EE29-6301-4E19-A823-933A46314951 Q30432299-2F36544D-D6AB-4565-8084-D874372A57D9 Q33738561-8AE8EB7A-5B3C-451B-9C01-21462CA1C3F3 Q34480466-81C6A4CB-CEBD-44ED-AFDC-1C7FB1FA7E55 Q35665777-F28B930D-6ECF-47C4-95E3-B8D1D375C7B2 Q36734220-09B8A1D2-CBA6-4C8A-B954-83C685446C0B Q37073823-6E79F5A9-C29E-452C-A196-96154B3A21D1 Q37551089-F72853A7-2545-4FDD-95C0-82FC72274B63 Q37592055-4DA5FB2B-3F3F-4463-A13D-8F9A508B7DD1 Q37730259-E26E67E8-C3C6-41CD-974B-7BEA735F5D30 Q38130161-B0E8A3A7-93BA-418C-B538-9E13C4C60B1A Q38233856-6DC4BCAA-D863-41B0-B7F8-0492039CC5DB Q38288028-E6F9E5AB-B11E-4096-BD9D-47048CB4A5D8 Q38538687-D6FC2E6E-1046-4ED4-B5D7-4CB3D4A5BAA7 Q38616538-FF0205E8-49E5-449E-95E8-A5C616751EC7 Q38662320-1207C231-91F8-4123-BA2C-3548233EB6E9 Q38809509-A0BAB9BF-6222-4266-8189-6970A0FF5E16 Q38810145-BD8FD90B-1EEB-441B-8547-5623EFEB1677 Q39013034-266C32D5-4F9F-4360-BE3E-F674BBE1453D Q39023026-BE552473-D644-4CDD-8AC6-8193CB5C03E5 Q42330134-DB0C6E2B-221E-4EA0-A62B-52C261F493BA Q43184339-9ABA90BD-0279-47F0-8510-CB93CC5C0060 Q46109875-147C9F33-D891-4CBC-B326-3BE00F52A111 Q47157713-FBA6D8BA-BA91-42DD-B98D-CD229E680D66 Q47648931-483B9C12-D897-4EBC-B9AB-F78BA2D1D424 Q47741857-9828F2BF-9D7B-47B5-BCED-F186E4F44CA4 Q50098235-2351756A-69D9-4609-95B9-C9D3ADC65323 Q51149216-7FC315E3-5FA6-4716-AED0-8AC9A334E844 Q51612566-55D94AB5-386B-4B60-9399-70199A469EDF Q52595214-F76737BA-42C2-446B-B7DF-DE727E457DD3 Q55447940-E76BA063-D3F4-4A37-9383-FB9AC65DADFB

P2860

Sildenafil preserves exercise capacity in patients with idiopathic pulmonary fibrosis and right-sided ventricular dysfunction.

http://www.wikidata.org/entity/Q30412726

description

2013 nî lūn-bûn

@nan

2013 թուականի Յունիսին հրատարակուած գիտական յօդուած

@hyw

2013 թվականի հունիսին հրատարակված գիտական հոդված

@hy

2013年の論文

@ja

2013年論文

@yue

2013年論文

@zh-hant

2013年論文

@zh-hk

2013年論文

@zh-mo

2013年論文

@zh-tw

2013年论文

@wuu

name

Sildenafil preserves exercise ...... sided ventricular dysfunction.

@ast

Sildenafil preserves exercise ...... sided ventricular dysfunction.

@en

type

label

Sildenafil preserves exercise ...... sided ventricular dysfunction.

@ast

Sildenafil preserves exercise ...... sided ventricular dysfunction.

@en

prefLabel

Sildenafil preserves exercise ...... sided ventricular dysfunction.

@ast

Sildenafil preserves exercise ...... sided ventricular dysfunction.

@en

P1433

Q30412726-862B9FA7-BA9F-429B-8794-08B6F5467934

P1476

Q30412726-5A21D4EC-F429-40F7-B3FA-1A54130E6C86

P2093

Q30412726-0CCC994A-EBC1-4BA9-AE18-BBE0BECCFE85

Q30412726-0FE310D6-DB47-4922-944B-F6CA2F6C79D2

Q30412726-5B5BD971-5772-4965-82EA-C39000DE0DD8

Q30412726-80165105-846B-44C2-91A1-9506AFC9136A

Q30412726-818160A3-5250-4ED3-B24F-AB7F74394C6E

Q30412726-D83D0848-C068-41B6-8BF3-B168FED34B52

Q30412726-E4E5EA9F-C63A-4260-A679-7A6E93584469

Q30412726-E864B829-EA18-4EC0-8144-9A25A7166047

P2860

Q30412726-04D8D9A1-FD78-42C4-BAF2-29C7365EAD8B

Q30412726-09B2ECAE-5189-4774-9D2D-C1C6E76C0944

Q30412726-19291D4C-E205-49B1-9049-120A54A1994C

Q30412726-2154187E-836C-40CE-A850-5CE461B6C031

Q30412726-2190E5E3-7340-465A-9E92-9E5AD733AEC2

Q30412726-2DBA91A8-A980-470D-A9D1-9C596C4A811A

Q30412726-379C3C82-BC08-4F6A-BE5A-1AD4AFFF2ACE

Q30412726-3C7A1337-0FE2-470D-AD3C-C38B1B0EE444

Q30412726-3EAE990E-3F2C-4698-AB54-47A418236B9D

Q30412726-49F411BB-EA4B-4ACF-B624-E2CB0E47BD04

P304

Q30412726-C9F26E62-0F15-4CA4-BE81-2E84CF339C1C

P31

Q30412726-CA33E3B3-BD96-4FC0-94FD-0142E4B1F216

P356

Q30412726-62606C3B-6FD8-4A6A-8EC9-3F60728276AE

P407

Q30412726-0B143DD6-EDB7-4C26-B4AB-D607C55E1887

P433

Q30412726-D5F8D904-A191-4F18-ABB8-1B9876E43426

P478

Q30412726-49065C24-0319-4B90-9264-8DD8F7237CC5

P50

Q30412726-4C74AD3B-054A-4904-8659-9FEB2B71FA06

P577

Q30412726-7D27BD2E-5558-4860-8BCC-D9CEDCE52A47

P698

Q30412726-B1F76FC2-AC19-4036-8010-F979E40355B6

P921

Q30412726-B8DE6D06-B305-4853-8A21-10CBAF4D8A61

Q30412726-D7E41EAB-520D-43A5-A8EB-6E3AED22E824

P932

Q30412726-A59C9C0D-7427-45FC-B6D3-74D46B361C82

P356

P1433

P1476

Sildenafil preserves exercise ...... sided ventricular dysfunction.

@en

P2093

David S Bach

http://www.w3.org/2001/XMLSchema#string

Eric Yow

http://www.w3.org/2001/XMLSchema#string

Fernando J Martinez

http://www.w3.org/2001/XMLSchema#string

Galen B Toews

http://www.w3.org/2001/XMLSchema#string

IPFnet Investigators

http://www.w3.org/2001/XMLSchema#string

Kevin R Flaherty

http://www.w3.org/2001/XMLSchema#string

MeiLan K Han

http://www.w3.org/2001/XMLSchema#string

Peter G Hagan

http://www.w3.org/2001/XMLSchema#string

P2860

BUILD-3: a randomized, controlled trial of bosentan in idiopathic pulmonary fibrosis

The SF-36 and SGRQ: validity and first look at minimum important differences in IPF.

Sildenafil citrate therapy for pulmonary arterial hypertension.

A controlled trial of sildenafil in advanced idiopathic pulmonary fibrosis.

Sildenafil improves walk distance in idiopathic pulmonary fibrosis.

Plasma endothelin-1 and vascular endothelial growth factor levels and their relationship to hemodynamics in idiopathic pulmonary fibrosis.

Estimation of minimally important differences in EQ-5D utility and VAS scores in cancer.

Updated evidence-based treatment algorithm in pulmonary arterial hypertension.

Pulmonary hypertension in idiopathic pulmonary fibrosis.

Pulmonary diseases and the heart.

P304

1699-1708

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1378/CHEST.12-1594

http://www.w3.org/2001/XMLSchema#string

P407

P433

6

http://www.w3.org/2001/XMLSchema#string

P478

143

http://www.w3.org/2001/XMLSchema#string

P50

Kevin J Anstrom

P577

2013-06-01T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P698

23732584

http://www.w3.org/2001/XMLSchema#string

P921

pulmonary fibrosis

P932

3673665

http://www.w3.org/2001/XMLSchema#string